Monoclonal Antibodies for Alzheimer Disease and Lecanemab’s Potential: Richard Isaacson, MD
The director of the Center for Brain Health and Alzheimer prevention clinic at FAU medicine shares his experience during the Medical Crossfire session on the Alheimer pipeline that he took part in at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 7 minutes]
IFN 2022 Recap With the Dementia Chair: Richard Isaacson, MD
The director of the Center for Brain Health and Alzheimer prevention clinic at FAU medicine shares his experience at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 3 minutes]
Future of Treating Alzheimer Disease
Drs Richard S. Isaacson and Marc E. Agronin look to the future of treating Alzheimer disease with the emphasis on early diagnosis.
Blood-Based Biomarkers for Diagnosis of Alzheimer Disease
The use of blood-based biomarkers for diagnosis of Alzheimer disease in the context of the comprehensive diagnosis.
Impact of the Approval of Aducanumab on the Treatment Landscape in Alzheimer Disease
Impact of the approval of aducanumab on the treatment landscape and other drugs in development for the treatment of Alzheimer disease.
Identifying the Appropriate Patient for Treatment with Aducanumab in Alzheimer Disease
The challenges of identifying the appropriate patient, earlier in the disease course, for treatment with aducanumab for Alzheimer disease.
EMBARK Phase III Clinical Trial of Aducanumab in Alzheimer Disease
The importance of the ongoing EMBARK phase III clinical trial and the collection of real-world data on the use of aducanumab is discussed.
FDA Approval of Aducanumab for Treatment of Alzheimer Disease
Expert neurologists, Richard S. Isaacson, MD, and Marc E. Agronin, MD, describe the journey to the FDA approval of aducanumab for the treatment of Alzheimer disease and what this means for clinicians.
2 Clarke Drive Cranbury, NJ 08512